US Stock Market Movement: Healthcare Services Surge on October 22 — Earnings Exceed Expectations, Guidance Raised, NEXDINE Acquisition
Bitget异动解读2026/10/22 15:05Healthcare Services October 22nd Surge Analysis
Keywords: Earnings Beat Expectations, Raised Guidance, NEXDINE Acquisition
1. On October 21st, the company announced its third quarter 2026 results, with diluted earnings per share of $0.36, higher than the market expectation of $0.22. Revenue was $479.6 million, up 3.3% year-on-year, slightly below estimates.
2. On October 21st, the company raised its 2027 revenue growth forecast from mid-single digits to low double digits and expects fourth quarter revenue to be between $535 million and $545 million.
3. On October 6th, the company completed its acquisition of NEXDINE Hospitality, with a transaction price of approximately $93.5 million. The company mainly provides environmental and dining services for medical institutions. NEXDINE is expected to contribute more than $150 million in annual revenue, with comparable profit margins, and is anticipated to be immediately accretive to earnings.
(Disclaimer: This content is a summary generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SpaceX says any potential merger with Tesla still requires further approval
Moderna plunges by as much as 26%, setting a record for the biggest single-day drop! Melanoma vaccine data leaked early, results fall short of expectations
Clinical trial data from phase 3 of the personalized melanoma vaccine jointly developed by Moderna and Merck was unexpectedly leaked ahead of schedule. The data showed a 42% reduction in cancer recurrence risk and a 38% reduction in risk of distant metastasis. These results fell short of market expectations, as an earlier study had shown the combination therapy could reduce recurrence risk by 49% and distant metastasis risk by 59%. Moderna's stock price plunged as much as 26% intraday, later rebounded partially, and ultimately closed down 17.6%.
SpaceX stated that the Tesla merger requires Elon Musk's approval.
Crypto prices
More
